Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain

被引:6
|
作者
Uo, T. [1 ]
Dvinge, H. [1 ,2 ,3 ]
Sprenger, C. C.
Bradley, R. K. [2 ,3 ]
Nelson, P. S. [4 ]
Plymate, S. R. [1 ]
机构
[1] Univ Washington, Dept Med, Harborview Res & Training Bldg,Box 359625,325 9th, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Computat Biol Program, 1124 Columbia St, Seattle, WA 98104 USA
[3] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA
[4] Fred Hutchinson Canc Res Ctr, Human Biol Div, 1124 Columbia St, Seattle, WA 98104 USA
关键词
HEAT-SHOCK PROTEIN; PROSTATE-CANCER; GLUCOCORTICOID-RECEPTOR; NUCLEAR-LOCALIZATION; INCREASED SURVIVAL; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; ACTIVATION; EXPRESSION;
D O I
10.1038/onc.2016.313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The presence of intact ligand-binding domain (LBD) ensures the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces structural reorganization of LBD resulting in release of AR from HSP90, suppression of nuclear export which otherwise dominates over import and nuclear translocation of AR as a transcription factor. Thus, loss or defects of the LBD abolish constraint from un-liganded LBD as exemplified by constitutively active AR variants (AR-Vs), which are associated with emerging resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC). Recent analysis of the AR splicing landscapes revealed mCRPC harboring multiple AR-Vs with diverse patterns of inclusion/exclusion of exons (exons 4-8) corresponding to LBD to produce namely exon-skipping variants. In silico construction for these AR-Vs revealed four novel AR-Vs having unique features: Exclusion of specified exons introduces a frameshift in variants v5es, v6es and v7es. ARv56es maintains the reading frame resulting in the inclusion of the C-terminal half of the LBD. We systematically characterized these AR-Vs regarding their subcellular localization, affinity for HSP90 and transactivation capability. Notably, ARv5es was free from HSP90, exclusively nuclear, and constitutively active similarly as previously reported for v567es. In contrast, v6es and v7es were similar in that they are cytoplasmic, transcriptionally inactive and bind HSP90, ARv56es was present in both nucleus and cytoplasm, does not bind HSP90 and is transcriptionally inactive. Converting these transcriptionally inactive AR-Vs into active forms, we identified the two separate elements that allosterically suppress otherwise constitutively active AR-Vs; one in exon 5 for v6es and v7es and the other in exon 8 for v56es. Our findings identify a novel constitutively active AR-V, ARv5es and establish a method to predict potential activities of AR-Vs carrying impaired LBD.
引用
收藏
页码:1440 / 1450
页数:11
相关论文
共 50 条
  • [31] Sequence variants of the ligand-binding domain of the glucocorticoid receptor gene and their functional consequences on the three dimensional protein structure
    Likó, I
    Igaz, P
    Patócs, A
    Tóth, S
    Pázmány, T
    Tóth, M
    Rácz, K
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (24) : 3229 - 3237
  • [32] Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor
    Harikumar, KG
    Miller, LJ
    PHARMACOLOGY & TOXICOLOGY, 2002, 91 (06): : 286 - 289
  • [33] Characterization of the extracellular ligand-binding domain of the type II activin receptor
    Greenwald, J
    Le, V
    Corrigan, A
    Fischer, W
    Komives, E
    Vale, W
    Choe, S
    BIOCHEMISTRY, 1998, 37 (47) : 16711 - 16718
  • [34] Alternative splicing in the ligand binding domain of mouse ApoE receptor-2 produces receptor variants binding reelin but not α2-macroglobulin
    Brandes, C
    Kahr, L
    Stockinger, W
    Hiesberger, T
    Schneider, WJ
    Nimpf, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) : 22160 - 22169
  • [35] Alternative splicing within the ligand binding domain of the human constitutive androstane receptor
    Savkur, RS
    Wu, YF
    Bramlett, KS
    Wang, MM
    Yao, SF
    Perkins, D
    Totten, M
    Searfoss, G
    Ryan, TP
    Su, EW
    Burris, TP
    MOLECULAR GENETICS AND METABOLISM, 2003, 80 (1-2) : 216 - 226
  • [36] Refolding and characterization of the functional ligand-binding domain of human lectin-like oxidized LDL receptor
    Xie, QH
    Matsunaga, S
    Shi, XH
    Ogawa, S
    Niimi, S
    Wen, ZS
    Tokuyasu, K
    Machida, S
    PROTEIN EXPRESSION AND PURIFICATION, 2003, 32 (01) : 68 - 74
  • [37] Dynamic communication between androgen and coactivator: Mutually induced conformational perturbations in androgen receptor ligand-binding domain
    Xu, Xue
    Yang, Wei
    Wang, Xia
    Li, Yan
    Wang, Yonghua
    Ai, Chunzhi
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2011, 79 (04) : 1154 - 1171
  • [38] Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain
    van de Wijngaart, Dennis J.
    van Royen, Martin E.
    Hersmus, Remko
    Pike, Ashley C. W.
    Houtsmuller, Adriaan B.
    Jenster, Guido
    Trapman, Jan
    Dubbink, Hendrikus J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (28) : 19407 - 19416
  • [39] A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations
    Doamekpor, Selom K.
    Peng, Panfeng
    Xu, Ruo
    Ma, Liandong
    Tong, Youzhi
    Tong, Liang
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2023, 79 : 95 - 104
  • [40] MUTATIONS IN THE LIGAND-BINDING DOMAIN OF THE ANDROGEN RECEPTOR GENE-CLUSTER IN 2 REGIONS OF THE GENE
    MCPHAUL, MJ
    MARCELLI, M
    ZOPPI, S
    WILSON, CM
    GRIFFIN, JE
    WILSON, JD
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05): : 2097 - 2101